Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.45 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26971276 | 0.83 | MEN1 (0.45) | MAOBIDO1MPOKMT2AHPGD | |
| SCHEMBL28223870 | 0.80 | HDAC1 (0.55) | MAOBIDO1HDAC1HDAC8HDAC6 | |
| SCHEMBL30030168 | 0.80 | MAOB (0.41) | MAOBIDO1MPO | |
| SCHEMBL26971146 | 0.80 | MAOB (0.41) | MAOBIDO1MPO | |
| SCHEMBL26971269 | 0.80 | MAOB (0.44) | MAOBMPOKMT2AKDM5AKDM4C | |
| SCHEMBL26971120 | 0.79 | IDO1 (0.50) | IDO1HDAC1HDAC6KDM4E | |
| SCHEMBL30679589 | 0.77 | LMNA (0.38) | KMT2AKDM4E | |
| SCHEMBL23286947 | 0.76 | MAOB (0.48) | MAOBIDO1MPOKMT2AKDM4E | |
| SCHEMBL26971117 | 0.76 | MAOB (0.45) | MAOBKDM5AKDM4CKDM4EHPGD | |
| SCHEMBL30031377 | 0.75 | MPO (0.45) | MAOBIDO1MPOHMOX1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858918-B2 | GLP-1R modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4271672-A1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-11-08 | — | — | EP | disclosed |
| WO-2022225941-A1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2022-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858918-B2 | GLP-1R modulating compounds | GLP1R, GIPR, GPR119 | MAOB 3970/4885IDO1 4145/4885MPO 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.